Published in J Clin Oncol on February 11, 2013
First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. J Clin Oncol (2015) 5.31
Influence of tumour micro-environment heterogeneity on therapeutic response. Nature (2013) 4.78
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. J Clin Oncol (2015) 3.24
VEGF targets the tumour cell. Nat Rev Cancer (2013) 2.71
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell (2014) 2.71
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest (2013) 2.03
Strategies for modern biomarker and drug development in oncology. J Hematol Oncol (2014) 1.89
Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience. PLoS One (2014) 1.43
Vascular endothelial growth factor a inhibition in gastric cancer. Gastric Cancer (2014) 1.07
Understanding and targeting resistance to anti-angiogenic therapies. J Gastrointest Oncol (2013) 1.05
Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene (2014) 1.04
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc Natl Acad Sci U S A (2015) 0.99
Biomarkers for anti-angiogenic therapy in cancer. Int J Mol Sci (2013) 0.96
Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Oncotarget (2016) 0.93
Sema3C promotes the survival and tumorigenicity of glioma stem cells through Rac1 activation. Cell Rep (2014) 0.92
Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer. J Thorac Dis (2014) 0.91
Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. Ann Oncol (2013) 0.91
Computational systems biology approaches to anti-angiogenic cancer therapeutics. Drug Discov Today (2014) 0.90
Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan. PLoS One (2013) 0.89
Discovery and functional assessment of gene variants in the vascular endothelial growth factor pathway. Hum Mutat (2013) 0.89
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat (2016) 0.88
Ziv-aflibercept in metastatic colorectal cancer. Biologics (2013) 0.88
Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab. PLoS One (2014) 0.88
Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma. Oncotarget (2014) 0.87
New developments in the treatment of ovarian cancer--future perspectives. Ann Oncol (2013) 0.86
Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment. EBioMedicine (2016) 0.84
Critical appraisal of bevacizumab in the treatment of ovarian cancer. Drug Des Devel Ther (2015) 0.83
Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. Br J Cancer (2014) 0.83
Future options of anti-angiogenic cancer therapy. Chin J Cancer (2016) 0.83
Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis. BMC Med (2016) 0.83
Neuropilin-1 as Therapeutic Target for Malignant Melanoma. Front Oncol (2015) 0.83
Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer. Cancer Sci (2014) 0.82
Can we identify predictive biomarkers for antiangiogenic therapy of cancer using mathematical modeling? J Natl Cancer Inst (2013) 0.82
Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival. BMC Cancer (2015) 0.81
Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge. Front Oncol (2015) 0.81
Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer. J Thorac Oncol (2015) 0.81
Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments. Ecancermedicalscience (2016) 0.81
A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer. Invest New Drugs (2014) 0.81
Ramucirumab: preclinical research and clinical development. Onco Targets Ther (2014) 0.81
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther (2014) 0.80
Tumor refractoriness to anti-VEGF therapy. Oncotarget (2016) 0.80
Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence. Onco Targets Ther (2014) 0.80
VEGFR targeting leads to significantly enhanced tumor uptake of nanographene oxide in vivo. Biomaterials (2014) 0.79
AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer. Gynecol Oncol (2014) 0.79
The emerging role of QSOX1 in cancer. Antioxid Redox Signal (2014) 0.79
Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial. Br J Cancer (2015) 0.78
Antiangiogenic therapy of brain tumors: the role of bevacizumab. Neurol Sci (2014) 0.78
Use of bevacizumab as a first-line treatment for metastatic breast cancer. Curr Oncol (2015) 0.78
Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer. Oncotarget (2016) 0.78
The prognostic significance of anti-angiogenesis therapy in ovarian cancer: a meta-analysis. J Ovarian Res (2015) 0.78
Angiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage? World J Gastroenterol (2013) 0.78
Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer. Br J Cancer (2015) 0.78
A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer. Sci Rep (2015) 0.78
Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study. Oncotarget (2015) 0.78
Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity. Cold Spring Harb Perspect Med (2016) 0.77
Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. Br J Cancer (2015) 0.77
Pre-Analytical Parameters Affecting Vascular Endothelial Growth Factor Measurement in Plasma: Identifying Confounders. PLoS One (2016) 0.77
Recent applications of chemosensitivity tests for colorectal cancer treatment. World J Gastroenterol (2014) 0.77
Profile of bevacizumab and its potential in the treatment of cervical cancer. Onco Targets Ther (2015) 0.77
Feasibility of novel PPP1R15A and proposed ANXA11 single nucleotide polymorphisms as predictive markers for bevacizumab regimen in metastatic colorectal cancer. J Cancer Res Clin Oncol (2016) 0.77
Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies. Oncotarget (2016) 0.76
Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma. J Neurol (2015) 0.76
Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes. Ther Adv Drug Saf (2014) 0.76
Impact of Serum Apolipoprotein A-I on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer: a Propensity Score-Matched Analysis. Transl Oncol (2017) 0.75
Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. World J Gastroenterol (2016) 0.75
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. Br J Cancer (2015) 0.75
Cholangiocarcinoma: Correlation between Molecular Profiling and Imaging Phenotypes. PLoS One (2015) 0.75
A Randomized Study of FOLFIRI plus either Panitumumab or Bevacizumab for Wild-Type KRAS Colorectal Cancer-WJOG 6210G. Cancer Sci (2016) 0.75
Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding. Oncotarget (2016) 0.75
Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations. Therap Adv Gastroenterol (2013) 0.75
A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis. Sci Rep (2016) 0.75
Update on Anti-Angiogenesis Therapy in Colorectal Cancer. Curr Colorectal Cancer Rep (2015) 0.75
Clinical Challenges to Current Molecularly Targeted Therapies in Lung Cancer. Arch Cancer Res (2016) 0.75
Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma. Expert Rev Mol Diagn (2016) 0.75
Expression of Heat Shock Protein 27 in Melanoma Metastases Is Associated with Overall Response to Bevacizumab Monotherapy: Analyses of Predictive Markers in a Clinical Phase II Study. PLoS One (2016) 0.75
Multi-scale mathematical modelling of tumour growth and microenvironments in anti-angiogenic therapy. Biomed Eng Online (2016) 0.75
A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer. BMC Cancer (2016) 0.75
Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy. Int J Mol Sci (2017) 0.75
Using Molecular Markers to Guide Therapy of Metastatic Colorectal Cancer. J Oncopathol (2013) 0.75
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses. J Natl Cancer Inst (2017) 0.75
[(18)F]FPRGD2 PET/CT imaging of integrin αvβ3 levels in patients with locally advanced rectal carcinoma. Eur J Nucl Med Mol Imaging (2015) 0.75
Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1. Oncotarget (2017) 0.75
The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing Chemotherapy. J Cancer (2017) 0.75
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (2012) 12.00
Colorectal cancer. Lancet (2010) 8.36
Hypoxia and inflammation. N Engl J Med (2011) 7.71
Gene prioritization through genomic data fusion. Nat Biotechnol (2006) 7.48
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet (2009) 6.99
Basic and therapeutic aspects of angiogenesis. Cell (2011) 6.40
uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol (2002) 6.24
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med (2002) 5.50
Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med (2002) 5.10
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell (2007) 5.09
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol (2008) 4.68
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19
Modification of kidney barrier function by the urokinase receptor. Nat Med (2007) 4.01
Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet (2008) 3.94
HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell (2011) 3.89
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol (2007) 3.85
The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84
The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Nature (2004) 3.77
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol (2008) 3.71
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest (2002) 3.70
A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. Proc Natl Acad Sci U S A (2004) 3.48
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer (2008) 3.46
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist (2007) 3.42
VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells. Dev Dyn (2006) 3.38
Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 3.34
Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci (2004) 3.31
Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell (2009) 3.27
A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature (2011) 3.25
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med (2003) 3.17
Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell (2002) 3.11
Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med (2015) 3.09
VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature (2004) 3.08
Role of PFKFB3-driven glycolysis in vessel sprouting. Cell (2013) 3.04
Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell (2011) 3.00
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol (2012) 2.92
Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol (2008) 2.91
VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays (2004) 2.83
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol (2007) 2.83
Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res (2005) 2.76
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75
Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J (2002) 2.74
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell (2013) 2.64
EGFR signaling and drug discovery. Oncology (2010) 2.53
Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med (2011) 2.49
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol (2012) 2.45
Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev (2002) 2.39
CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res (2005) 2.38
VEGF receptor 2 endocytic trafficking regulates arterial morphogenesis. Dev Cell (2010) 2.37
Protective role of reactive astrocytes in brain ischemia. J Cereb Blood Flow Metab (2007) 2.35
Influence of sex on the survival of patients with esophageal cancer. J Clin Oncol (2012) 2.29
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol (2006) 2.29
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell (2010) 2.26
Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 2.20
VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J (2006) 2.20
Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci (2008) 2.15
Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov (2009) 2.10
The FGF system has a key role in regulating vascular integrity. J Clin Invest (2008) 2.09
Regulation of angiogenesis by oxygen and metabolism. Dev Cell (2009) 2.04
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest (2013) 2.03
Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood (2009) 2.01
Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer (2011) 2.01
Endothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequent fatty liver disease in mice. J Clin Invest (2008) 2.00
Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest (2003) 2.00
Role and therapeutic potential of VEGF in the nervous system. Physiol Rev (2009) 1.98
Oxygen sensors at the crossroad of metabolism. Cell Metab (2009) 1.98
Mouse Aortic Ring Assay: A New Approach of the Molecular Genetics of Angiogenesis. Biol Proced Online (2002) 1.91
Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation (2004) 1.91
Mechanisms of vessel branching: filopodia on endothelial tip cells lead the way. Arterioscler Thromb Vasc Biol (2009) 1.91
Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell (2005) 1.89
Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med (2004) 1.89
The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist (2007) 1.89
Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology (2007) 1.88
Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol (2008) 1.88
A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics (2004) 1.88
Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes. Blood (2007) 1.86
Activation of the UNC5B receptor by Netrin-1 inhibits sprouting angiogenesis. Genes Dev (2007) 1.86
The neurovascular link in health and disease: molecular mechanisms and therapeutic implications. Neuron (2011) 1.85
A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nat Med (2005) 1.85
VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ Res (2003) 1.82
An Msh2 point mutation uncouples DNA mismatch repair and apoptosis. Cancer Res (2004) 1.81
Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility. Cancer Cell (2004) 1.81
Urokinase-type plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm. Circ Res (2003) 1.81
VEGF: a modifier of the del22q11 (DiGeorge) syndrome? Nat Med (2003) 1.79
Selective regulation of arterial branching morphogenesis by synectin. Dev Cell (2006) 1.77
Overlap syndrome of cardiac sodium channel disease in mice carrying the equivalent mutation of human SCN5A-1795insD. Circulation (2006) 1.76
Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer. J Clin Oncol (2007) 1.75
Systemic and targeted delivery of semaphorin 3A inhibits tumor angiogenesis and progression in mouse tumor models. Arterioscler Thromb Vasc Biol (2011) 1.75
Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest (2006) 1.75
Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway. Genes Dev (2008) 1.73
A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res (2003) 1.73
Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol (2011) 1.72
Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst (2002) 1.72
Soluble VEGF isoforms are essential for establishing epiphyseal vascularization and regulating chondrocyte development and survival. J Clin Invest (2004) 1.72
Plasmin is not protective in experimental renal interstitial fibrosis. Kidney Int (2004) 1.71
The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J (2002) 1.70
Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity. Cancer Cell (2012) 1.69
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol (2008) 1.69